Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editor in chief, John Sterling, interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Richard A. Gibbs, Ph.D. received a B.Sc.(Hons) in 1979 and a Ph.D. in Genetics and Radiation Biology in 1985 at the University of Melbourne, Melbourne, Australia. He subsequently moved to Houston as a Postdoctoral Fellow at Baylor College of Medicine to study the molecular basis of human X-linked diseases and to develop technologies for rapid genetic analysis. During this period, he also developed several fundamental technologies for nucleic acid analysis. In 1991, he joined the faculty at BCM and played a key role in the early planning and development phases of the International Human Genome Project. In 1996, he established the Human Genome Sequencing Center (HGSC) when Baylor was chosen as one of six worldwide sites to complete the final phase of the project. He currently holds the rank of Director and Professor.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »